Stem Cell Clinic

Novel Therapies Needed: Poor Prognosis of Patients With TP53-Mutated Myeloid Malignancies – Cancer Therapy Advisor

By Stem Cell Medicine

Poorprognosis and limited efficacy of intensive chemotherapy approaches forpatients with TP53-mutated myeloidmalignancies were confirmed in study results published in Leukemia &Lymphoma.

Jan Philipp Bewersdorf, MD, of the department of internal medicine, section of hematology at the Yale School of Medicine in New Haven, Connecticut, and colleagues conducted the single-center retrospective cohort study from September 1, 2015, to May 31, 2019 (follow-up ended on July 4, 2019). The aims of the study were to describe the clinical, cytogenetic, and molecular characteristics of patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) with TP53 mutations and to analyze patient responses and outcomes with different treatment modalities.

Ofthe 83 participants in the study, the majority were Caucasian (88%); 51.8% werewomen and the median age was 69 years. Most patients had complex karyotypes(90%), and nearly 40% of patients developed therapy-related malignancies.

Frontline treatment included intensive chemotherapy (24.1%), low-intensity treatment (42.2%), best supportive care or hydroxyurea only (22.9%), targeted therapy (3.6%), or other treatments (8.4%).

Themedian follow up was 6.4 months. The median overall survival (OS) and 1-year OSrate were 7.6 months and 22.6%, respectively. Among patients with AML, the medianOS was 6.7 months and 1-year OS rate was 16%. Among patients with MDS, themedian OS was 10 months and the 1-year OS rate was 31.1%.

Forpatients with AML, intensive chemotherapy did not improve median OS compared withlow-intensity treatment (8.8 months vs 9.4 months, respectively; hazard ratio[HR], 0.63). The 1-year OS rates for intensive chemotherapy and low-intensitytherapy were 25.0% and 14.3%, respectively (P =.46); complete response rates were 45.0% and 14.3%, respectively.

Amongparticipents with MDS, no patients received induction chemotherapy as frontlinetreatment. For the 19 patients with MDS who received hypomethylating agent-basedtherapies, the median OS was 12.1 months. For patients who received hydroxyureaor best supportive care only, the median OS was 0.8 months.

Notably,the 11 patients who underwent allogeneic hematopoietic stem cell transplant (alloHSCT)had a significantly longer median OS than those who did not (HR, 0.08; P =.002).Therefore, the authors suggested the alloHSCT should be considered for eligiblepatients with TP53-mutated myeloidneoplasms.

Limitationsof the study included the retrospective design, small sample size, and shortfollow-up durations.

Inconclusion, our data confirm the limited efficacy of intensive chemotherapyapproaches for TP53-mutated patientswith myeloid neoplasms and suggest that a minority of patients achievelong-term survival with alloHSCT, wrote the authors.

Reference

Bewersdorf JP, Shallis RM, Gowda L, et al. Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience [published online May 2, 2020]. Leuk Lymphoma. doi: 10.1080/10428194.2020.1759051

This article originally appeared on Hematology Advisor

Read more from the original source:
Novel Therapies Needed: Poor Prognosis of Patients With TP53-Mutated Myeloid Malignancies - Cancer Therapy Advisor

Clinical Outcomes Using RYONCIL(TM) (remestemcel-L) in Children and Adults With Severe Inflammatory Graft Versus Host Disease Published in Three…

By Stem Cell Medicine

Key points:

NEW YORK, May 25, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that clinical outcomes of its allogeneic mesenchymal stem cell (MSC) medicine RYONCIL (remestemcel-L) in children and adults with steroid-refractory acute graft versus host disease (GVHD) have been published in three peer-reviewed articles and an accompanying editorial in the May issue of Biology of Blood and Marrow Transplantation, the official publication of the American Society for Transplantation and Cellular Therapy.

Mesoblast Chief Medical Officer Dr Fred Grossman said: Results from these three trials show a consistent pattern of safety and efficacy for RYONCIL (remestemcel-L) in patients with the greatest levels of inflammation and the most severe grades of acute GVHD. These clinical outcomes provide a compelling rationale for use of remestemcel-L in children and adults with other conditions associated with severe inflammation and cytokine release, including acute respiratory distress syndrome (ARDS) and systemic vascular manifestations of COVID-19 infection.”

In the accompanying editorial, Dr Jacques Galipeau, Professor and Assistant Dean of Medicine at the Stem Cell & Regenerative Medicine Center at the University of WisconsinMadison and Chair of the International Society of Cell and Gene Therapy (ISCT) MSC Committee, concluded that after more than a decade of clinical study involving three distinct advanced trials, it appears that remestemcel-L might well have finally met the regulatory requirements for marketing approval in the United States for steroid refractory acute GVHD in children, and it is to be determined whether this industrial MSC product will find utility for adults afflicted by acute GVHD or other indications.

The trials highlighted in the three articles all evaluated the same treatment regimen of RYONCIL, with patients receiving twice weekly intravenous infusions of 2 million cells per kg body weight over a four-week period. RYONCIL was well-tolerated in all studies with no identified safety concerns. The three trials were:

1. Study 275: An Expanded Access Program in 241 children across 50 centers in eight countries where RYONCIL was used as salvage therapy for steroid-refractory acute GVHD in patients who failed to respond to steroid therapy as well as multiple other agents.

2. Study GVHD001/002: A Phase 3 single-arm trial in 55 children across 20 centers in the United States where RYONCIL was used as the first line of treatment for children who failed to respond to steroids for acute GVHD.

3. Study 280: A Phase 3 randomized placebo-controlled trial in 260 patients, including 28 children, across 72 centers in seven countries where RYONCIL or placebo were added to second line therapy in patients with steroid-refractory acute GVHD who failed to respond to steroid treatment.

About Acute Graft Versus Host Disease Acute GVHD occurs in approximately 50% of patients who receive an allogeneic bone marrow transplant (BMT). Over 30,000 patients worldwide undergo an allogeneic BMT annually, primarily during treatment for blood cancers, and these numbers are increasing.1 In patients with the most severe form of acute GVHD (Grade C/D or III/IV) mortality is as high as 90% despite optimal institutional standard of care.2,3 There are currently no FDA-approved treatments in the United States for children under 12 with steroid-refractory acute GVHD.

About RYONCILTM Mesoblast’s lead product candidate, RYONCIL (remestemcel-L), is an investigational therapy comprising culture-expanded mesenchymal stem cells derived from the bone marrow of an unrelated donor. It is administered to patients in a series of intravenous infusions. RYONCIL is believed to have immunomodulatory properties to counteract the inflammatory processes that are implicated in SR-aGVHD by down-regulating the production of pro-inflammatory cytokines, increasing production of anti-inflammatory cytokines, and enabling recruitment of naturally occurring anti-inflammatory cells to involved tissues.

References 1. Niederwieser D, Baldomero H, Szer J. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplant 2016; 51(6):778-85. 2. Westin, J., Saliba, RM., Lima, M. (2011) Steroid-refractory acute GVHD: predictors and outcomes. Advances in Hematology 2011;2011:601953. 3. Axt L, Naumann A, Toennies J (2019) Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation 2019;54(11):1805-1814.

About Mesoblast Mesoblast Limited (Nasdaq:MESO; ASX:MSB) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast’s Biologics License Application to seek approval of its product candidate RYONCIL (remestemcel-L) for pediatric steroid-refractory acute graft versus host disease (acute GVHD) has been accepted for priority review by the United States Food and Drug Administration (FDA), and if approved, product launch in the United States is expected in 2020. Remestemcel-L is also being developed for other inflammatory diseases in children and adults including moderate to severe acute respiratory distress syndrome. Mesoblast is completing Phase 3 trials for its product candidates for advanced heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblast’s licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets.

Mesoblast has a strong and extensive global intellectual property (IP) portfolio with protection extending through to at least 2040 in all major markets. This IP position is expected to provide the Company with substantial commercial advantages as it develops its product candidates for these conditions.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see http://www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast

Forward-Looking Statements This announcement includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of Mesoblast and its collaborators’ clinical studies; Mesoblast and its collaborators’ ability to advance product candidates into, enroll and successfully complete, clinical studies; the timing or likelihood of regulatory filings and approvals; and the pricing and reimbursement of Mesoblast’s product candidates, if approved; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

For further information, please contact:

View post:
Clinical Outcomes Using RYONCIL(TM) (remestemcel-L) in Children and Adults With Severe Inflammatory Graft Versus Host Disease Published in Three...

Kyle Larson’s First Payday After His NASCAR Suspension is Smaller Than You Might Think – Sportscasting

By Stem Cell Doctors

Kyle Larson may not be allowed to compete in NASCAR events any time soon, but that isnt stopping him from winning races in the meantime. Larson won the World of Outlaws sprint car race on Saturday at Federated Auto Parts Raceway in St. Louis. It was his first race since he was suspended indefinitely by NASCAR for using a racial slur during a virtual iRacing event. Even though he won the race, the check wasnt as lucrative as Larson is used to.

RELATED: Jimmie Johnsons Historic NASCAR Career Is Ending in Frustrating Fashion

If youre wondering why Kyle Larson is racing in sprint car events instead of NASCAR races, it all stems from an iRacing incident from last month.

During a virtual NASCAR race on April 12, Larson uttered a racial slur while streaming on Twitch. Larson thought no one could hear him through his microphone, but the entire group of drivers and the thousands of viewers picked up the slur.

The next day, NASCAR suspended Larson indefinitely. Larson was fired by Chip Ganassi Racing after the incident, and he also lost all of his primary sponsorships.

Larson might not be able to compete on the NASCAR stage for now, but hes still able to race in other leagues while he serves his suspension. On Saturday, he returned to the track for the third time since the racial slur incident, and he even won the race.

Larson competed in the World of Outlaws sprint car race during Memorial Day Weekend. Unlike NASCAR, the race was held on a dirt track with smaller, slower cars and quicker turns. The difference didnt phase Larson in the slightest, as he went on to win the race.

Larson said he was happy for everyone who has stuck behind us after my mistake there. It means a lot. Im having a blast. Trying to have as much fun as I can anyways. Trying to keep my mind off things.

It might not get NASCAR fans to like him again, but Larsons win proved he can still race at a high level despite the controversy swirling around him.

In NASCAR, the purses can range from around $1 million to over $20 million. The winner of a certain race can walk away an instant millionaire, but thats not the case in sprint car races.

Sprint car races are far less popular than NASCAR races, so the television coverage and overall purses are much lower. Larson took home just $20,000 for his win on Saturday. If he was still racing in NASCAR, the payday wouldve been much larger.

Maybe his less than stellar prize will serve as a wake-up call for Larson. He undoubtedly wants to return to NASCAR soon because of the stronger competition and larger purses, but hell have to serve time in lower racing leagues for a while for what he said last month.

Go here to read the rest:
Kyle Larson's First Payday After His NASCAR Suspension is Smaller Than You Might Think - Sportscasting

COVID-19: The Prevention Prescription – The New Indian Express

By Stem Cell Doctors

The health focus today is squarely on the bodys natural defense system. Until there is a vaccination, preventative measures are all we can turn to. Ayurveda can help, experts believe, especially a technique thats been gaining popularity. It's called Photo Bio Modulation (PBM). Availableat Indus Valley AyurvedicCentre (IVAC) in Mysore, itsan emerging medical practicein which exposure to low-level laser light or light-emitting diodes stimulates cellular function. This results in beneficial clinical outcomes for various conditions and diseases, primarily low immunity, in addition to lung disorders, respiratory disorders, joint problems, skin issues, and stress.

How does it work?Also known as Low-Level Laser Therapy (LLLT), it increases the production of Adenosine Triphosphate (ATP) in the mitochondria of the cells, which scavenges the free radicals. By doing so, it stimulates stem cell proliferation, lymph nodes associated with respiratory tract, the immune system and stimulates local tissues to support lung function leading to protection from asthma, bronchitis, pneumonia and Chronic Obstructive Pulmonary Disease, says Dr Talavane Krishna, Founder,President, IVAC.

Nasal ApplicationWhile PBM is gaining prominence now, processes such as nasal application, part of Panchakarma (five actions) treatment, have been a standard Ayurvedic antidote to viruses for aeons. One has to apply different herbal powders, liquid extracts, medicated ghee or oil inside the nostrils. Medications like Anu Taila, sesame or coconut oil, Brahmi ghrutha etc are antimicrobial and act as a protective filter inside the nose and throatthe primary entry point for the viruses. This simple procedure could be a daily practice for both adults and children.

Oil pulling Likewise, oil pulling with sesame or coconut oil as a daily oral health practice is useful. It involves swishing a teaspoon of oil in the mouth for three-five minutes and then spitting the oil, followed by washing/brushing the mouth. This kills bacteria that may lead to tooth decay, bad breath, and gum disease.

Rasayana This is one of the eight major branches of Ayurveda. Popularly known as a form of rejuvenation therapy, not only does it focus on anti-aging, but also immunity. This is accomplished by taking certain Ayurvedic preparations, food based on body constitution, and following an Ayurvedic way of life. This increases Ojas, the very essence of the bodys immunity. Medicines include single herbs like Ashwagandha, Shatavari, Amrita, and formulations like Chyavanaprash, Triphala, Makaradhwaja, notto mention regular body-mind detoxifications like Panchakarma and Rejuvenation.

Balance is keyKeeping the body alignedwith its natural rhythms is a prerequisite to the success of your health. For this, Ayurvedic principles namely Dhincharya (daily regime) and Rithucharya (seasonal regime) are crucial. Dhinacharya looks at aspects such as oral hygiene, yoga, pranayama, meditation, diet, bowel movements and more. Ritucharya describes the various changes in our body during the different seasonsand its effect on health. Italso teaches us how to keepa good balance.

The importance of dietcannot be negated, therefore ensure you add ginger, garlic, pepper, turmeric, clove, cumin, fenugreek and cinnamon in your food as all these ingredients build the immunesystem and bring aboutperfect balance, says Gita Ramesh, Joint MD, Kairali Ayurvedic Group.Dont forget to take warm showers and apply sesame oil on the entire body before the morning bath. Allow nostrils to be lubricated by application of cow ghee or oil, and do warm turmeric water gargles regularly, says Dr Aruna Bhide, Senior Ayurveda Doctor and Consultant, Mercure Goa Devaaya Retreat. Breathing exerciseslike Anulom vilom pranayama (alternate breathing), Kapal bhati (forceful exhalation) and Nadi shuddhi pranayama are beneficial too. Keep in mind to exercise until you sweat as this is the best way to excrete toxins.

Potions for healing(Do consult an Ayurvedic doctor)

Indukantha Kashyam Prevents the recurrence of debilitating diseases and keeps the body healthyVilwadi GulikaA tablet used as a treatment for insect bites, rodent bites, gastroenteritis etc.

Chyawanprash High in Vitamin C, it aids in the production of haemoglobinand white blood cells

Kushmandarasayana Comes in a herbal jam form and is used in respiratory conditions

TriphalaGhritam Support bowel health and aids digestion. As an antioxidant, its also thought to detoxify the body and support immunity.

AshwagandhaIt has demonstrated excellent immune-boosting effects, and has also shown to encourage anti-inflammatory and disease-fighting immune cells, thatkeep illnesses at bay

Amrita Used as a blood purifierMakaradhwaja A mineral-based preparation used for its aphrodisiac characteristics, it enhances the effectiveness of several medicines

View post:
COVID-19: The Prevention Prescription - The New Indian Express

We must follow the rules to keep out coronavirus – Gulf News

By Stem Cell Doctors

We have to obey the rules. No country is equipped to handle a pandemic of this proportion Image Credit: Gulf News

Have you been staying at home? Were you practising social distancing when you had to go out? Did you wear a mask outdoors? We hope all of you did. And in the next few days, as we mark the Eid, you should stick to these measures to ensure your safety and the safety of others. As responsible citizens and residents, its our duty to follow theguidelines to help the UAE fight the scourge of COVID-19.

Ramadan is a time for prayer, reflection and family iftars. But this fasting month has come at a time when the world has been battling a global pandemic. Caution is the watchword now. Thats why the UAE and other countries have asked people to refrain from gathering for iftar and Taraweeh prayers.

People in the UAE have generally adhered to the rules as each of the emirates carry out its own disinfection drive. But there have been instances where some people have shown scant regard for the guidelines.

A family gathering turned out to be a disaster as 31 people who attended the iftar party were found to have been infected by the virus. This is precisely the situation that UAE officials have sought to avoid.

The UAE is well aware of the risks when it partially opened the malls and parks, resumed the operation of Dubai Metro. It is important for the economy and the mental well-being of the people. However, officials expect people to do their part in safeguarding themselves and society at large. That would mean following the rules strictly.

But there have been violations. And these irresponsible actions are counterproductive, making it difficult for the authorities to rein in the spread of the virus. Hefty fines and more restrictions are a result of the scale of violations. These fines are essential to dissuade people from putting others in danger.

No country is equipped to handle a pandemic of this proportion. Think of the medical professionals who put their lives at risk every day. They work courageously in the face of grave danger to save us from the virus. We should recognise their sacrifice by acting responsibly; by averting any possible exposure to coronavirus. That would make the work of doctors, nurses and paramedics easier.

Each of us owes our health to ourselves. More importantly, we are vital cogs in keeping the UAE healthy. Lets do our part: stay home, wash hands as often as possible, practise social distancing, wear masks (preferably gloves too) outdoors, and follow the guidelines. That way, we would have played our part in the global battle against coronavirus.

See more here:
We must follow the rules to keep out coronavirus - Gulf News

1st transplant using liver cells from embryonic stem cells conducted on baby in Japan – The Mainichi

By Embryonic Stem Cells

This photo provided by the National Center for Child Health and Development shows liver cells produced from embryonic stem cells.This photo provided by the National Center for Child Health and Development shows human embryonic stem cells.

The National Center for Child Health and Development in Tokyo announced it has successfully conducted a clinical trial to transplant liver cells created from human embryonic stem cells into a baby with a serious liver condition.

It is the first clinical trial in Japan to use human embryonic stem cells, and is also believed to be the first case in the world of liver cells produced from embryonic stem cells being transplanted into a person.

The baby that received the transplant had hyperammonemia, a condition in which an abnormality in the natural urea cycle prevents toxic ammonia from being broken down in the liver. The abnormality is said to be prevalent in between one in 8,000 and one in 44,000 people.

In serious cases a liver transplant is required to treat it, but newborns have a high risk of experiencing major side effects. As a result, transplants cannot be conducted safely until several months after birth, when the baby weighs 6 kilograms or more.

In Europe and North America, doctors have utilized translational medicine, in which normally functioning liver cells are transplanted into newborns, to keep the liver functioning until an organ transplant can be carried out. In Japan, the National Center for Child Health and Development has previously transplanted liver cells from living donors into newborns with the condition soon after birth, but it has had difficulty in steadily securing liver cells.

Because of this, the center drew up plans to create liver cells from embryonic stem cells and transplant them. Over a period of two days in October 2019, it injected about 190 million liver cells into blood vessels in the umbilical cord of a 6-day-old newborn with hyperammonemia. The ammonia concentration in the infant's blood then stopped rising, enabling researchers to confirm that the liver cells had reached the newborn's liver, and the baby was temporarily discharged from the hospital.

Five months later, when the baby weighed 7 kilograms, a living donor liver transplant was carried out with the baby's father serving as the donor. The baby was again able to be discharged from the hospital in late April.

The center has received approval from the national government to use liver cells derived from embryonic stem cells in regenerative medicine, and plans to transplant them into several people subject to clinical trials in the future.

Center official Mureo Kasahara of the national center's organ transplant center commented, "It was often the case that babies with this condition died from seizures or suffered brain damage before the liver transplant could take place. The latest case is hugely significant in that we have proved the effectiveness of the method."

(Japanese original by Ayumu Iwasaki, Science & Environment News Department)

More:
1st transplant using liver cells from embryonic stem cells conducted on baby in Japan - The Mainichi

Global Stem Cell Reconstructive Market- Industry Analysis and Forecast… – Azizsalon News

By Embryonic Stem Cells

Global Stem Cell Reconstructive Marketwas valued US$ XX Mn in 2019 and is expected to reach US$ XX Mn by 2027, at a CAGR of 24.5% during a forecast period.

Market Dynamics

The Research Report gives an in-depth account of the drivers and restraints in the stem cell reconstructive market. Stem cell reconstructive surgery includes the treatment of injured or dented part of body. Stem cells are undifferentiated biological cells, which divide to produce more stem cells. Growing reconstructive surgeries led by the rising number of limbs elimination and implants and accidents are boosting the growth in the stem cell reconstructive market. Additionally, rising number of aged population, number of patients suffering from chronic diseases, and unceasing development in the technology, these are factors which promoting the growth of the stem cell reconstructive market. Stem cell reconstructive is a procedure containing the use of a patients own adipose tissue to rise the fat volume in the area of reconstruction and therefore helping 3Dimentional reconstruction in patients who have experienced a trauma or in a post-surgical event such as a mastectomy or lumpectomy, brain surgery, or reconstructive surgery as a result of an accident or injury. Stem cell reconstructive surgeries are also used in plastic or cosmetic surgeries as well. Stem cell and regenerative therapies gives many opportunities for development in the practice of medicine and the possibility of an array of novel treatment options for patients experiencing a variety of symptoms and conditions. Stem cell therapy, also recognised as regenerative medicine, promotes the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/54666/

The common guarantee of all the undifferentiated embryonic stem cells (ESCs), foetal, amniotic, UCB, and adult stem cell types is their indefinite self-renewal capacity and high multilineage differentiation potential that confer them a primitive and dynamic role throughout the developmental process and the lifespan in adult mammal.However, the high expenditure of stem cell reconstructive surgeries and strict regulatory approvals are restraining the market growth.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Global Stem Cell Reconstructive Market Segment analysis

Based on Cell Type, the embryonic stem cells segment is expected to grow at a CAGR of XX% during the forecast period. Embryonic stem cells (ESCs), derived from the blastocyst stage of early mammalian embryos, are distinguished by their capability to distinguish into any embryonic cell type and by their ability to self-renew. Owing to their plasticity and potentially limitless capacity for self-renewal, embryonic stem cell therapies have been suggested for regenerative medicine and tissue replacement after injury or disease. Additionally, their potential in regenerative medicine, embryonic stem cells provide a possible another source of tissue/organs which serves as a possible solution to the donor shortage dilemma. Researchers have differentiated ESCs into dopamine-producing cells with the hope that these neurons could be used in the treatment of Parkinsons disease. Upsurge occurrence of cardiac and malignant diseases is promoting the segment growth. Rapid developments in this vertical contain protocols for directed differentiation, defined culture systems, demonstration of applications in drug screening, establishment of several disease models, and evaluation of therapeutic potential in treating incurable diseases.

Global Stem Cell Reconstructive Market Regional analysis

The North American region has dominated the market with US$ XX Mn. America accounts for the largest and fastest-growing market of stem cell reconstructive because of the huge patient population and well-built healthcare sector. Americas stem cell reconstructive market is segmented into two major regions such as North America and South America. More than 80% of the market is shared by North America due to the presence of the US and Canada.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/54666/

Europe accounts for the second-largest market which is followed by the Asia Pacific. Germany and UK account for the major share in the European market due to government support for research and development, well-developed technology and high healthcare expenditure have fuelled the growth of the market. This growing occurrence of cancer and diabetes in America is the main boosting factor for the growth of this market.

The objective of the report is to present a comprehensive analysis of the Global Stem Cell Reconstructive Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding Global Stem Cell Reconstructive Market dynamics, structure by analysing the market segments and projects the Global Stem Cell Reconstructive Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Stem Cell Reconstructive Market make the report investors guide.Scope of the Global Stem Cell Reconstructive Market

Global Stem Cell Reconstructive Market, By Sources

Allogeneic Autologouso Bone Marrowo Adipose Tissueo Blood Syngeneic OtherGlobal Stem Cell Reconstructive Market, By Cell Type

Embryonic Stem Cell Adult Stem CellGlobal Stem Cell Reconstructive Market, By Application

Cancer Diabetes Traumatic Skin Defect Severe Burn OtherGlobal Stem Cell Reconstructive Market, By End-User

Hospitals Research Institute OthersGlobal Stem Cell Reconstructive Market, By Regions

North America Europe Asia-Pacific South America Middle East and Africa (MEA)Key Players operating the Global Stem Cell Reconstructive Market

Osiris Therapeutics NuVasives Cytori Therapeutics Takeda (TiGenix) Cynata Celyad Medi-post Anterogen Molmed Baxter Eleveflow Mesoblast Ltd. Micronit Microfluidics TAKARA BIO INC. Tigenix Capricor Therapeutics Astellas Pharma US, Inc. Pfizer Inc. STEMCELL Technologies Inc.

MAJOR TOC OF THE REPORT

Chapter One: Stem Cell Reconstructive Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Stem Cell Reconstructive Market Competition, by Players

Chapter Four: Global Stem Cell Reconstructive Market Size by Regions

Chapter Five: North America Stem Cell Reconstructive Revenue by Countries

Chapter Six: Europe Stem Cell Reconstructive Revenue by Countries

Chapter Seven: Asia-Pacific Stem Cell Reconstructive Revenue by Countries

Chapter Eight: South America Stem Cell Reconstructive Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Stem Cell Reconstructive by Countries

Chapter Ten: Global Stem Cell Reconstructive Market Segment by Type

Chapter Eleven: Global Stem Cell Reconstructive Market Segment by Application

Chapter Twelve: Global Stem Cell Reconstructive Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Stem Cell Reconstructive Market Report at:https://www.maximizemarketresearch.com/market-report/global-stem-cell-reconstructive-market/54666/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

Read the original:
Global Stem Cell Reconstructive Market- Industry Analysis and Forecast... - Azizsalon News

Anti-Aging: HGH Can Reduce Biological Age by One Year and a Half Study Shows – Gilmore Health News

By Embryonic Stem Cells

Researchers have been able to reduce the biological age of nine people by administering synthetic growth hormone injections (HGH) for 12 months.

HGH Injections

A lot of research is being done around the world to rejuvenate body cells and slow down the aging process. One of them, published in the journal Cell Aging, suggests that a persons biological clock can be set back a year and a half. A feat in the race against time.

Read Also: Do HGH Supplements Like Genf20 Plus, GenfX, Hypergh 14X, HGH X2 and Provacyl Work?

Nine healthy men aged 51 to 65 took a synthetic growth hormone (HGH) to stimulate the thymus gland, a small gland located in the upper thorax between the lungs. The thymus gland plays an important role in the immune system, but atrophies with age and loses its effectiveness.

Using blood samples taken before and after the experiment, researchers from the University of California found that the epigenetic age of the participants was reduced by one and a half years in 12 months of treatment. Epigenetics is the study of changes in gene activity: it measures the biological age of a person, i.e. the age of their cells, not their chronological age.

Read Also: Is NAD+ The Anti Aging Substance Mankind Has Been Searching For?

This strongly suggests that their risk of mortality has decreased without us being able to give an accurate estimate of their life expectancy, says Steve Horvath, Professor of Biostatistics and lead author of the study. However, this study, which was conducted only on white males in a single age group, needs to be conducted on a larger sample of people of different ages, ethnicity, and gender. A new trial with 50 participants is planned.

Recently, researchers at Stanford University succeeded in rejuvenating human cells with the help of proteins involved in the early stages of embryonic development and induced pluripotent stem cells, more simply called iPS (for induced pluripotent stem cells).

Read Also: HGH May Help Heal Age-Induced Tissue Damage By Activating Vital Gene

When iPS cells are produced from adult cells, they become younger and pluripotent, said Vittorio Sebastiano, assistant professor at Stanford University. For a while we wondered whether it would not be possible to simply stop the aging clock without inducing pluripotency, i.e. the ability to reproduce. And we succeeded, said the researchers, who were able to rejuvenate the cells of several people.

References

Reversal of epigenetic aging and immunosenescent trends in humans

Related Articles:

HGH and Its Anti Aging Effects On The Skin

NAD Plus An Anti-Aging Supplement Could Play A Big Role in The Treatment of Cancer

Is The Cancer Drug Dasatinib The Anti-Aging Breakthrough We Have All Been Waiting For?

HGH Benefits: What to Expect From Using Human Growth Hormone

HGH Side Effects: Is HGH Worth the Risks and Are There Safe Alternatives?

HGH Deficiency Symptoms And Latest Testing Options

More:
Anti-Aging: HGH Can Reduce Biological Age by One Year and a Half Study Shows - Gilmore Health News

Clinical Outcomes Using RYONCIL (remestemcel-L) in Children and Adults With Severe Inflammatory Graft Versus Host Disease Published in Three Articles…

By Stem Cell Treatment

Key points:

NEW YORK, May 25, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that clinical outcomes of its allogeneic mesenchymal stem cell (MSC) medicine RYONCIL (remestemcel-L) in children and adults with steroid-refractory acute graft versus host disease (GVHD) have been published in three peer-reviewed articles and an accompanying editorial in the May issue of Biology of Blood and Marrow Transplantation, the official publication of the American Society for Transplantation and Cellular Therapy.

Mesoblast Chief Medical Officer Dr Fred Grossman said: Results from these three trials show a consistent pattern of safety and efficacy for RYONCIL (remestemcel-L) in patients with the greatest levels of inflammation and the most severe grades of acute GVHD. These clinical outcomes provide a compelling rationale for use of remestemcel-L in children and adults with other conditions associated with severe inflammation and cytokine release, including acute respiratory distress syndrome (ARDS) and systemic vascular manifestations of COVID-19 infection.

In the accompanying editorial, Dr Jacques Galipeau, Professor and Assistant Dean of Medicine at the Stem Cell & Regenerative Medicine Center at the University of WisconsinMadison and Chair of the International Society of Cell and Gene Therapy (ISCT) MSC Committee, concluded that after more than a decade of clinical study involving three distinct advanced trials, it appears that remestemcel-L might well have finally met the regulatory requirements for marketing approval in the United States for steroid refractory acute GVHD in children, and it is to be determined whether this industrial MSC product will find utility for adults afflicted by acute GVHD or other indications.

The trials highlighted in the three articles all evaluated the same treatment regimen of RYONCIL, with patients receiving twice weekly intravenous infusions of 2 million cells per kg body weight over a four-week period. RYONCIL was well-tolerated in all studies with no identified safety concerns. The three trials were:

1. Study 275: An Expanded Access Program in 241 children across 50 centers in eight countries where RYONCIL was used as salvage therapy for steroid-refractory acute GVHD in patients who failed to respond to steroid therapy as well as multiple other agents.

2. Study GVHD001/002: A Phase 3 single-arm trial in 55 children across 20 centers in the United States where RYONCIL was used as the first line of treatment for children who failed to respond to steroids for acute GVHD.

3. Study 280: A Phase 3 randomized placebo-controlled trial in 260 patients, including 28 children, across 72 centers in seven countries where RYONCIL or placebo were added to second line therapy in patients with steroid-refractory acute GVHD who failed to respond to steroid treatment.

About Acute Graft Versus Host Disease Acute GVHD occurs in approximately 50% of patients who receive an allogeneic bone marrow transplant (BMT). Over 30,000 patients worldwide undergo an allogeneic BMT annually, primarily during treatment for blood cancers, and these numbers are increasing.1 In patients with the most severe form of acute GVHD (Grade C/D or III/IV) mortality is as high as 90% despite optimal institutional standard of care.2,3 There are currently no FDA-approved treatments in the United States for children under 12 with steroid-refractory acute GVHD.

About RYONCILTM Mesoblasts lead product candidate, RYONCIL (remestemcel-L), is an investigational therapy comprising culture-expanded mesenchymal stem cells derived from the bone marrow of an unrelated donor. It is administered to patients in a series of intravenous infusions. RYONCIL is believed to have immunomodulatory properties to counteract the inflammatory processes that are implicated in SR-aGVHD by down-regulating the production of pro-inflammatory cytokines, increasing production of anti-inflammatory cytokines, and enabling recruitment of naturally occurring anti-inflammatory cells to involved tissues.

References 1. Niederwieser D, Baldomero H, Szer J. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplant 2016; 51(6):778-85.2. Westin, J., Saliba, RM., Lima, M. (2011) Steroid-refractory acute GVHD: predictors and outcomes. Advances in Hematology 2011;2011:601953.3. Axt L, Naumann A, Toennies J (2019) Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation 2019;54(11):1805-1814.

About MesoblastMesoblast Limited (Nasdaq:MESO; ASX:MSB) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. The Companys proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblasts Biologics License Application to seek approval of its product candidate RYONCIL (remestemcel-L) for pediatric steroid-refractory acute graft versus host disease (acute GVHD) has been accepted for priority review by the United States Food and Drug Administration (FDA), and if approved, product launch in the United States is expected in 2020. Remestemcel-L is also being developed for other inflammatory diseases in children and adults including moderate to severe acute respiratory distress syndrome. Mesoblast is completing Phase 3 trials for its product candidates for advanced heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblasts licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets.

Mesoblast has a strong and extensive global intellectual property (IP) portfolio with protection extending through to at least 2040 in all major markets. This IP position is expected to provide the Company with substantial commercial advantages as it develops its product candidates for these conditions.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see http://www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast

Forward-Looking StatementsThis announcement includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of Mesoblast and its collaborators clinical studies; Mesoblast and its collaborators ability to advance product candidates into, enroll and successfully complete, clinical studies; the timing or likelihood of regulatory filings and approvals; and the pricing and reimbursement of Mesoblasts product candidates, if approved; the potential benefits of strategic collaboration agreements and Mesoblasts ability to maintain established strategic collaborations; Mesoblasts ability to establish and maintain intellectual property on its product candidates and Mesoblasts ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblasts actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

For further information, please contact:

Read the original:
Clinical Outcomes Using RYONCIL (remestemcel-L) in Children and Adults With Severe Inflammatory Graft Versus Host Disease Published in Three Articles...

Stem Cell Therapy Market 2020: Consumption, Trends, Growth, Types,Industrial Applications, Leading Companies & Forecast till 2026 – Jewish Life…

By Stem Cell Treatment

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Stem Cell Therapy market.

Trusted Business Insights presents an updated and Latest Study on Stem Cell Therapy Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Stem Cell Therapy market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Stem Cell Therapy Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Abstract, Snapshot, Market Analysis & Market Definition: Stem Cell Therapy MarketIndustry / Sector Trends

Stem Cell Therapy Market size was valued at USD 7.8 billion in 2018 and is expected to witness 10.2% CAGR from 2019 to 2025.

U.S. Stem Cell Therapy Market Size, By Type, 2018 & 2025 (USD Million)

Rising prevalence of chronic diseases will positively impact the stem cell therapy market growth. Cardiovascular diseases, neurological disorders and other chronic conditions have resulted in high mortality over past few years. Conventional therapeutic methods and treatments are currently replaced due to lack of efficiency and efficacy. Recently developed stem cell therapies are capable of replacing defective cells to treat diseases that has reduced morbidity drastically. Therefore, people have now started relying on stem cell therapy that has long term positive effects.

Advancements in stem cell therapy in developed regions such as North America and Europe have boosted the industry growth. Since past few years, there have been several researches carried out for stem cell therapy. Currently developed stem cell therapies have shown positive outcomes in treatment of leukemia. Similarly, due to advancements in regenerative medicine, several other chronic conditions such as muscular dystrophy and cardiovascular diseases also have been cured. Aforementioned factors have surged the industry growth. However, high cost of allogenic stem cell therapy may hamper the industry growth to some extent.

Market Segmentation, Outlook & Regional Insights: Stem Cell Therapy Market

Stem Cell Therapy Market, By Type

Allogenic stem cell therapy segment held around 39% revenue share in 2018 and it is anticipated to grow substantially during analysis timeframe. Allogenic stem cell is available as off the shelf therapy and it is easily scalable that helps in providing treatment without delay. Moreover, the procedure includes culturing donor-derived immunocompetent cells that are highly effective in treatment of several diseases. Stem cells obtained in allogenic therapy are free of contaminating tumor cells. This reduces risk for disease recurrence that will surge its demand thereby, stimulating segment growth.

Autologous stem cell therapy segment is estimated to witness 10.1% growth over the forthcoming years. People usually prefer autologous stem cell therapy as it has minimum risk of immunological rejection. However, on introduction of allogenic stem cell therapy, demand for autologous stem cell therapy has declined as it is difficult to scale up. However, there are concerns regarding risk of cross contamination during large scale manufacturing of autologous stem cell lines that will impede segmental growth to some extent.

Stem Cell Therapy Market, By Application

Neurology segment was valued around USD 1.6 billion in 2018 and it is estimated that it will witness significant growth over the forthcoming years. Stem cells are used to replenish the disrupted neurological cells that helps in quick patient recovery. Pluripotent stem cells provide replacement for cells and tissues to treat Alzheimers, Parkinsons disease, cerebral palsy, amyotrophic lateral sclerosis and other neurodegenerative diseases. Thus, pivotal role of stem cells in treating life threatening neurological condition will escalate segment growth.

Cardiovascular segment will witness 10% growth over the analysis timeframe. Considerable segmental growth can be attributed to development in stem cell therapies that have enhanced recovery pace in patients suffering from cardiovascular diseases. Recently developed allogenic stem cell therapies are efficient and easily available that have reduced the mortality rates in cardiovascular patients. Above mentioned factors will propel cardiovascular segment growth in near future.

Germany Stem Cell Therapy Market Size, By Application, 2018 (USD Million)

Stem Cell Therapy Market, By End-users

Hospitals segment held over 56% revenue share in 2018 and it is anticipated to grow significantly in near future. Rising preference for stem cell therapies offered by hospitals proves beneficial for the business growth. Hospitals have affiliations with research laboratories and academic institutes that carry out research activities for developing stem cell therapies. On introduction and approval of any novel stem therapy, hospitals implement it immediately. Associations with research and academic institutes further helps hospitals to upgrade its stem cell treatment offerings that positively impacts the segmental growth.

Clinics segment is expected to grow at around 10% during the forecast timeframe. Clinics specializing in providing stem cell therapies are well-equipped with advanced medical devices and superior quality reagents required for imparting stem cell therapies. However, as clinics offer specialized stem cell therapies, their treatment cost is much higher as compared to hospitals that may reduce its preference.

Stem Cell Therapy Market, By Region

North America stem cell therapy market held around 41.5% revenue share in 2018 and it is estimated to grow substantially in near future. Increasing adoption of novel stem cell therapies will prove beneficial for regional market growth. Moreover, favourable government initiatives have positive impact on the regional market growth. For instance, government of Canada has initiated Strategic Innovation Fund Program that invests in research activities carried out for stem cell therapies enabling development in stem cell therapy. Above mentioned factors are expected to drive the North America market growth.

Asia Pacific stem cell therapy market is anticipated to witness 10.8% growth in near future owing to increasing awareness amongst people pertaining to benefits of advanced stem cell therapies. Additionally, favourable initiatives undertaken by several organizations will promote industry players to come up with innovative solutions. For instance, according to Pharma Focus Asia, members of Asia-Pacific Economic Cooperation collaborated with Life Sciences Innovation Forum to involve professionals having expertise in stem cell therapies from academia and research centers to promote developments in stem cell research. Thus, growing initiatives by organizations ensuring availability of new stem cell therapies will foster regional market growth.

Latin America Stem Cell Therapy Market Size, By Country, 2025 (USD Million)

Key Players, Recent Developments & Sector Viewpoints: Stem Cell Therapy Market

Key industry players in stem cell therapy market include Astellas Pharma Inc, Cellectis, Celyad, Novadip Biosciences, Gamida Cell, Capricor Therapeutics, Cellular Dynamics, CESCA Therapeutics, DiscGenics, OxStem, Mesoblast Ltd, ReNeuron Group and Takeda Pharmaceuticals. Chief industry players implement several initiatives such as mergers and acquisitions to sustain market competition. Also, receiving approvals for stem cell therapy products from regulatory authorities fosters companys growth. For instance, in March 2018, European Commission approved Takedas Alofisel that is off-the-shelf stem cell therapy. Product approval will help company to gain competitive advantage and capture market share.

Stem Cell Therapy Industry Viewpoint

Stem cells industry can be traced back to 1950s. In 1959 first animals were made by in-vitro fertilization by preserving the stem cells. Till 2000, research was being carried out on stem cells to study its therapeutic effect. In 2000, fund allocations were made to research on cells derived from aborted human foetuses. In the same year, scientists derived human embryonic stem cells from the inner cell mass of blastocytes. Later, in 2010, clinical trials for human embryonic stem cell-based therapy were initiated. As technology progressed, stem cell therapy for treating cancer were developed. However, due to ethical issues, the use of stem cells for curing diseases witnessed slow growth for few years. But as the regulatory scenario changed, people started preferring stem cell therapies due to its better efficacy. Stem cell therapy is in developing stage and has numerous growth opportunities in developing economies with high prevalence of chronic diseases.

Key Insights Covered: Exhaustive Stem Cell Therapy Market1. Market size (sales, revenue and growth rate) of Stem Cell Therapy industry.2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Stem Cell Therapy industry.3. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Stem Cell Therapy industry.4. Market size (sales, revenue) forecast by regions and countries from 2019 to 2025 of Stem Cell Therapy industry.

Research Methodology: Stem Cell Therapy Market

Quick Read Table of Contents of this Report @ Stem Cell Therapy Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Read the rest here:
Stem Cell Therapy Market 2020: Consumption, Trends, Growth, Types,Industrial Applications, Leading Companies & Forecast till 2026 - Jewish Life...

→←